245 results on '"Nüesch, E"'
Search Results
2. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
3. A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study
4. An examination chair to measure internal rotation of the hip in routine settings: a validation study
5. Integrating fragmented evidence by network meta-analysis: relative effectiveness of psychological interventions for adults with post-traumatic stress disorder
6. The prevalence of widespread central hypersensitivity in chronic pain patients
7. Glucosamine and chondroitin for osteoarthritis of the hip or knee
8. A randomised controlled trial of spinal manipulative therapy in acute low back pain
9. Pharmacokinetic investigation of oral and IV dihydroergotamine in healthy subjects
10. Pharmacokinetics of isradipine in patients with chronic liver disease
11. Abstract P6-17-30: Changes in patient, tumor, and treatment characteristics over time in first-line trastuzumab plus taxane (paclitaxel/docetaxel) arms in HER2-positive metastatic breast cancer trials
12. A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study
13. Extension of the loo-riegelman method to pharmacokinetic data at steady state
14. MetaPHER phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer : First results
15. OHERA: A real world study of cardiac events in > 3700 patients with her2-positive early breast cancer treated with trastuzumab: Final analysis
16. 1025MO First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours
17. The effects of exclusions of patients from the analysis in randomised controlled trials: Meta-epidemiological study
18. Abstract P4-21-42: MetaPHER phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer: First results
19. Bioavailability studies with Digoxin-Sandoz® and Lanoxin®
20. Analgesic activity of propyphenazone in patients with pain following oral surgery
21. A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet
22. Pharmacokinetics of oral cyclosporin a (Sandimmun) in healthy subjects
23. Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone
24. Pharmacokinetic comparison of pindolol 30 mg retard and 15 mg normal tablets
25. Pharmacokinetics of unlabelled and14C-labelled pindolol in uraemia
26. Assessment of analgesics in dental surgery outpatients
27. Pharmacokinetic criteria for the evaluation of retard formulations
28. Ein Thermostat hoher Konstanz
29. Proof of the general validity of Dost's law of corresponding areas
30. Standardized mean differences may be used to derive odds ratios of treatment response: meta-epidemiological study
31. Pooled standardised mean differences and estimated heterogeneity between trials depend on the type of assessment tool analysed: meta-epidemiological study
32. 410O_PR - Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study
33. MA 07.01 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial
34. JCES 01.27 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial
35. 1298O_PR - Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study
36. 175P - OHERA: A real world study of cardiac events in > 3700 patients with her2-positive early breast cancer treated with trastuzumab: Final analysis
37. Irrungen und Wirrungen bei einer kontroversen Arthrosetherapie
38. Irrungen und Wirrungen bei der Erforschung von Arthrosetherapien
39. The effects of exclusions of patients from the analysis in randomised controlled trials: Meta-epidemiological study | [Ausschluss von patienten aus der analyse: Auswirkungen auf die ergebnisse randomisierter kontrollierter studien: Eine meta-epidemiologische studie]
40. Empirical evidence of attrition bias in meta-analyses of randomized controlled trials Abstract [Oral abstract O02-7]
41. Overestimation of treatment effects associated with small sample size in osteoarthritis research [Abstract P08-79]
42. Bias associated with inadequate or unclear concealment of allocation in randomized osteoarthritis trials [Abstract P08-77]
43. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data
44. OP0192 Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia
45. Prevalence of cam and pincer-type deformities on hip MRI in an asymptomatic young Swiss female population: a cross-sectional study
46. Admission Serum Glucose Levels: An Independent Risk Factor predicting Short- and Long-term Mortality in Community Acquired Pneumonia
47. Systolic blood pressure below 110mmHG is associated with increased mortality in blunt major trauma patents: Multicentre Cohort Study
48. 342 ALL-CAUSE AND DISEASE-SPECIFIC MORTALITY IN PATIENTS WITH KNEE OR HIP OSTEOARTHRITIS: POPULATION-BASED COHORT STUDY
49. Irrungen und Wirrungen bei einer kontroversen Arthrosetherapie
50. Irrungen und Wirrungen bei der Erforschung von Arthrosetherapien
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.